Certara, Inc. (CERT)Healthcare | Health Information Services | Radnor, United States | NasdaqGS
6.79 USD
+0.02
(0.295%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:06 a.m. EDT
The investment case for Certara is currently broken by a catastrophic multi-year decline. The stock has lost nearly 60% of its value over the last four years, with every single year showing negative returns. This is not a temporary correction; it is a structural deterioration where the market has repeatedly rejected the business's value proposition. Fundamentals confirm the distress: the company is posting losses, has negative equity returns, and faces significant regulatory probes and executive instability. While the partnership with NVIDIA offers a glimmer of hope for future relevance, it cannot instantly reverse four years of compounding destruction. The balance sheet is fragile, and the lack of a dividend leaves shareholders with no income buffer. On the short end, the heavy put writing suggests traders are betting on further weakness or simply protecting existing capital, making a near-term bounce unlikely without a major catalyst. This is a 'avoid' situation where the pain of holding is likely to continue until the company proves it can stabilize its operations and earnings. |
| Model | MAE |
|---|---|
| MSTL_126 ✓ | 0.084134 |
| AutoTheta | 0.097754 |
| AutoARIMA | 0.098338 |
| AutoETS | 0.098338 |
| MSTL | 0.099499 |
| MSTL_90_126 | 0.102508 |
| MSTL_90 | 0.117647 |
Forecast horizon: 60 days | Selected: MSTL_126
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 4.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.508 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.955 |
| Revenue per Share | 2.63 |
| Market Cap | 1,056,283,712 |
| Forward P/E | 16.40 |
| Beta | 1.46 |
| Profit Margins | -3.60% |
| Website | https://www.certara.com |
As of July 11, 2026, 3:06 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with deep out-of-the-money puts holding substantial volume relative to calls. The skew in implied volatility is extreme, with put IV far exceeding call IV, indicating a market pricing in a high probability of further decline. While there is some call activity at the $10 strike, the dominant theme is hedging against a drop to the $5 level.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.39228004 |
| Address1 | 4 Radnor Corporate Center |
| Address2 | Suite 350 |
| All Time High | 45.48 |
| All Time Low | 4.45 |
| Ask | 8.67 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 5,926,990 |
| Average Daily Volume3 Month | 4,080,611 |
| Average Volume | 4,080,611 |
| Average Volume10Days | 5,926,990 |
| Beta | 1.459 |
| Bid | 5.05 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 6.633 |
| City | Radnor |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.79 |
| Current Ratio | 1.877 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 7.06 |
| Day Low | 6.74 |
| Debt To Equity | 29.955 |
| Display Name | Certara |
| Earnings Call Timestamp End | 1,778,502,600 |
| Earnings Call Timestamp Start | 1,778,502,600 |
| Earnings Timestamp | 1,778,502,600 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | 94,029,000 |
| Ebitda Margins | 0.22400999 |
| Enterprise To Ebitda | 12.884 |
| Enterprise To Revenue | 2.886 |
| Enterprise Value | 1,211,429,632 |
| Eps Current Year | 0.384 |
| Eps Forward | 0.41391 |
| Eps Trailing Twelve Months | -0.1 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.711 |
| Fifty Day Average Change | 1.079 |
| Fifty Day Average Change Percent | 0.18893364 |
| Fifty Two Week Change Percent | -39.228004 |
| Fifty Two Week High | 13.88 |
| Fifty Two Week High Change | -7.09 |
| Fifty Two Week High Change Percent | -0.5108069 |
| Fifty Two Week Low | 4.45 |
| Fifty Two Week Low Change | 2.3400002 |
| Fifty Two Week Low Change Percent | 0.5258427 |
| Fifty Two Week Range | 4.45 - 13.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,607,697,000,000 |
| Float Shares | 107,283,576 |
| Forward Eps | 0.41391 |
| Forward P E | 16.404531 |
| Free Cashflow | 116,569,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,515 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.61591 |
| Gross Profits | 258,526,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0257 |
| Held Percent Institutions | 1.1181301 |
| Implied Shares Outstanding | 155,564,608 |
| Industry | Health Information Services |
| Industry Disp | Health Information Services |
| Industry Key | health-information-services |
| Ipo Expected Date | 2,020-12-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania. |
| Long Name | Certara, Inc. |
| Market | us_market |
| Market Cap | 1,056,283,712 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_100474847 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -15,101,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,055,505,865 |
| Number Of Analyst Opinions | 10 |
| Open | 6.83 |
| Operating Cashflow | 90,667,000 |
| Operating Margins | 0.03798 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 415 237 8272 |
| Pre Market Change | -0.13999987 |
| Pre Market Change Percent | -2.0618536 |
| Pre Market Price | 6.65 |
| Pre Market Time | 1,784,017,017 |
| Previous Close | 6.77 |
| Price Eps Current Year | 17.682291 |
| Price Hint | 2 |
| Price To Book | 1.0236696 |
| Price To Sales Trailing12 Months | 2.5164652 |
| Profit Margins | -0.03598 |
| Quick Ratio | 1.784 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.27273 |
| Region | US |
| Regular Market Change | 0.02 |
| Regular Market Change Percent | 0.295421 |
| Regular Market Day High | 7.06 |
| Regular Market Day Low | 6.74 |
| Regular Market Day Range | 6.74 - 7.06 |
| Regular Market Open | 6.83 |
| Regular Market Previous Close | 6.77 |
| Regular Market Price | 6.79 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,972,809 |
| Return On Assets | 0.00751 |
| Return On Equity | -0.01437 |
| Revenue Growth | 0.009 |
| Revenue Per Share | 2.63 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 155,564,608 |
| Shares Percent Shares Out | 0.1889 |
| Shares Short | 29,382,164 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 28,750,194 |
| Short Name | Certara, Inc. |
| Short Percent Of Float | 0.2926 |
| Short Ratio | 5.99 |
| Source Interval | 15 |
| State | PA |
| Symbol | CERT |
| Target High Price | 10.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 7.48 |
| Target Median Price | 7.65 |
| Total Cash | 149,510,000 |
| Total Cash Per Share | 0.961 |
| Total Debt | 304,656,000 |
| Total Revenue | 419,748,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.1 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.965625 |
| Two Hundred Day Average Change | -1.1756248 |
| Two Hundred Day Average Change Percent | -0.14758727 |
| Type Disp | Equity |
| Volume | 1,972,809 |
| Website | https://www.certara.com |
| Zip | 19,087 |